002872.SZ(002872.SZ)
002872.SZ
$5.95—Stale · unknown old
SHZ • Last print unknown ago
$5.95—Stale · unknown old
Tiansheng Pharmaceutical Group Co., Ltd. specializes in the research, development, and manufacturing of innovative biopharmaceuticals, primarily targeting oncology and autoimmune diseases. The company operates primarily in China, leveraging its proprietary drug formulations and a growing pipeline of clinical trials to differentiate itself in a competitive market.
Tiansheng generates revenue through the sale of patented pharmaceuticals, focusing on niche therapeutic areas where it holds competitive advantages due to its proprietary formulations and established relationships with healthcare providers. The company also engages in research collaborations with larger pharmaceutical firms, enhancing its revenue diversification.
Regulatory approvals for new drug candidates
Clinical trial results impacting drug efficacy and safety
Partnership announcements with larger pharmaceutical companies
Market penetration in emerging therapeutic areas
Regulatory changes impacting drug approval processes
Technological disruptions in drug development methodologies
Emergence of generic competitors for key products
Increased R&D spending by larger pharmaceutical companies
Negative operating margins leading to cash flow constraints
Potential reliance on external financing for ongoing R&D
moderate - The biotechnology sector is somewhat insulated from economic cycles, but funding for R&D can be affected by broader economic conditions.
Higher interest rates can increase the cost of capital for R&D funding, potentially delaying product development and impacting valuations.
minimal - The company has low debt levels, which reduces its sensitivity to credit market fluctuations.
growth - Investors are likely attracted to the potential for high returns from successful drug development.
high - The stock has historically exhibited high volatility due to the binary nature of clinical trial outcomes.